10.1111/j.1365-2125.2006.02690.xBritish Journal of Clinical Pharmacology624457-472BCPH
447-452In view of documented evidence that catechol estrogen-DNA adducts serve as epitopes for bin...
to hematologic malignancies may be medi-ated in part through polymorphic variability in the bioactiv...
Polymorphic light eruption (PLE) is a common skin disease, susceptibility to which is genetically de...
Aims Cyclophosphamide (CTX) is an established treatment of severe systemic lupus erythematosus (SLE)...
Aims Cyclophosphamide (CTX) is an established treatment of severe systemic lupus erythematosus (SLE)...
Background Lupus nephritis (LN) occurs in up to 60% of adults with systemic lupus erythematosus (SLE...
To assess whether the CYP2C19 polymorphism modified the effect of cyclophosphamide on ovarian toxici...
Oxidative stress caused by poor detoxification efficiency of reactive oxygen species (ROS) may play ...
Objective. Cyclophosphamide (CYC) is an immunosuppressant drug widely used to treat various diseases...
A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is t...
ABSTRACT. Objective. Cyclophosphamide (CYC) is an immunosuppressant drug widely used to treat variou...
OBJECTIVE: Ovarian toxicity is a major concern with cyclophosphamide (CYC) therapy. CYC is a prodrug...
Objective: Ovarian toxicity is a major concern with cyclophosphamide (CYC) therapy. CYC is a prodrug...
<p><strong>Background:</strong> Chemotherapy often causes side effects such as hematologic toxicity....
Objective. We have observed several cases of patients with systemic lupus erythematosus (SLE) who de...
447-452In view of documented evidence that catechol estrogen-DNA adducts serve as epitopes for bin...
to hematologic malignancies may be medi-ated in part through polymorphic variability in the bioactiv...
Polymorphic light eruption (PLE) is a common skin disease, susceptibility to which is genetically de...
Aims Cyclophosphamide (CTX) is an established treatment of severe systemic lupus erythematosus (SLE)...
Aims Cyclophosphamide (CTX) is an established treatment of severe systemic lupus erythematosus (SLE)...
Background Lupus nephritis (LN) occurs in up to 60% of adults with systemic lupus erythematosus (SLE...
To assess whether the CYP2C19 polymorphism modified the effect of cyclophosphamide on ovarian toxici...
Oxidative stress caused by poor detoxification efficiency of reactive oxygen species (ROS) may play ...
Objective. Cyclophosphamide (CYC) is an immunosuppressant drug widely used to treat various diseases...
A 6-month cyclophosphamide induction therapy followed by maintenance therapy every three months is t...
ABSTRACT. Objective. Cyclophosphamide (CYC) is an immunosuppressant drug widely used to treat variou...
OBJECTIVE: Ovarian toxicity is a major concern with cyclophosphamide (CYC) therapy. CYC is a prodrug...
Objective: Ovarian toxicity is a major concern with cyclophosphamide (CYC) therapy. CYC is a prodrug...
<p><strong>Background:</strong> Chemotherapy often causes side effects such as hematologic toxicity....
Objective. We have observed several cases of patients with systemic lupus erythematosus (SLE) who de...
447-452In view of documented evidence that catechol estrogen-DNA adducts serve as epitopes for bin...
to hematologic malignancies may be medi-ated in part through polymorphic variability in the bioactiv...
Polymorphic light eruption (PLE) is a common skin disease, susceptibility to which is genetically de...
DOI
Add to ORKG